Get notified when TNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Departure Of Cfo (new) — The Board determined the CFO would no longer serve, with no disclosed reason for the departure.
NASDAQ: TNGX Tango Therapeutics, Inc. 8-K

Tango Therapeutics CFO Daniella Beckman departs; Matthew Gall appointed new CFO

Filed April 15, 2026 · Period ending April 10, 2026 · ~1 min read

Key Changes

  • high

    CFO Daniella Beckman ceased serving effective April 15, 2026, after the Board determined she would no longer hold the role. No reason for the departure was disclosed.

    Item 5.02 verify on EDGAR →
  • high

    Matthew Gall, 49, appointed new CFO effective April 15, 2026. Previously served as CFO of Kalaris Therapeutics and iTeos Therapeutics, bringing biotech finance experience.

    Item 5.02 verify on EDGAR →
  • medium

    Gall's compensation includes $540,000 base salary, 40% target bonus, options for 240,000 shares vesting over four years, and 40,000 restricted stock units vesting over three years.

    Employment Agreement verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.

Partner

Trade TNGX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify